Transforming the Experience for Patients Living with Congestive Heart Failure: Services, Protocols and Results
|
|
- Alice Shannon Johnston
- 5 years ago
- Views:
Transcription
1 Transforming the Experience for Patients Living with Congestive Heart Failure: Services, Protocols and Results Iain Findlay Scotland
2 HF Epidemiology World pandemic 26 millions patients (15 millions in Europe) General Prevalence 1-2% ( >70 years old >10%) 1/5 adults will have HF symptoms 1/8 death certificates incudes HF as one of the causes (USA) 2/3 admissions could be prevented Quality of life McMurray et al. EHJ 2012; Cowie et al. EHJ 2013; Go A S et al. Circulation. 2014
3 High hospitalisations rates Most common cause of hospitalisation >65y Emergency admissions >5% Primary diagnosis: 1-4% >50% >80y Germany: +40% (2000-7) UK: +57% ( ) Spain: +22% ( ) USA: 1 million/y (stable) Typical progression of AHF Baker, DW et al. Am Heart J 2003; 146(2): Ho KK, et al. Circulation 1993; 88(1): Jong P, et al. Arch Int Med 2002; 162(15) Narang R,et al. Eur Heart J 1996; 17(9) ED visits: > 3% LOS = 5-10 days Cowie et al. ESC-HF 2014: Improving care for patients with AHF Go A S et al. Circulation. 2014;129:e28-e292
4 Number LOS in days
5 Sicker than we think!!! More deaths from HF than from all forms of cancer combined Rehospitalisations Mortality: 30-day: 20-25% In-hospital: 4-10% 1-year: 60-70% 30-day: 10-13% 1-year: 20-40% Disease Comparative 5-years mortality CHF 60-70% Adenocarcinoma of the colon (IIIB) 36% COPD (FEV % predicted) 53% ESRD (dialysis-dependent) 60-80% Cowie et al. ESC-HF 2014: Improving care for patients with AHF Baker, DW et al. Am Heart J 2003; 146(2): Ho KK, et al. Circulation 1993; 88(1): Jong P, et al. Arch Int Med 2002; 162(15) Narang R,et al. Eur Heart J 1996; 17(9)
6 Disease population Direct cost of CHF management varies between 1-3% of total healthcare costs > 65 years old> 75% of total cost Disease prevalence projected to increase by about 46% in the next years 18/03/2016 United4Health Year 3 Review 6
7 Tele-Health Available Evidence Publications in PubMed
8 Transforming the Experience for Patients Living with Congestive Heart Failure: Services, Protocols and Results Iain Findlay Scotland
9 Protocol Eligibility criteria Hospitalisation or ED visit for decompensated HF in the previous 6 months AND, at least one of the following three conditions: LVEF < 45% LVEF > 45% but BNP > 400 Confirmed diagnosis of CHF by a cardiologist 18/03/2016 United4Health Year 3 Review 9
10 Heart Failure Risk Stratification 2215 people diagnosed with Heart Failure in Renfrewshire and East Renfrewshire (Source: GP QOF register as at 1/8/14) Full telehealth package Usual Care 6 (0.1%) had 3 admissions Case Management 23 (1.2%) of people had 2 hospital admissions Anticipatory Care Plan (ACP) Care Management 224(10.1%) of people had 1 hospital admission Lite Touch Telehealthcare Patient led supported self management Disease specific co-ordination Simple Telehealth Supported Self Management 1962 (88.6%) people diagnosed with Heart Failure not admitted Web based remote health coaching, interactive educational programmes, NHS inform, Living it Up, Digital TV, Digital Postcards Note: Calculations are based on emergency admissions for exacerbation of HF duringfinancial year 2013/14
11 Protocol- study follow-up period Intervention group: Enrolment started on 1st January 2014 and continued until 31st March Patients screened: 1,106 Patients evaluated: 611 (control and intervention) Comparator group: Prospective collection of the data Minimum follow-up for the evaluation: 6 months 18/03/2016 United4Health Year 3 Review 11
12 Generic telehealth configuration & key interactions 18/03/2016 United4Health Year 3 Review 12
13 CHF pilot version of
14 Headline Impact of study Clinical Patient Economic
15 Population characteristics Intervention (n=277) Comparator (n=334) P-value Age (years) 72.5± ± Male (n, %) 197 (71%) 189 (57%) Smokers (n, %) 18 (7.2%) 21 (6.8%) >0.05 BMI (kg/m 2 ) 29.1± ± SBP (mmhg) 131±22 138± DBP (mmhg) 76±14 79± LVEF (%) 40±14 42± egfr (MDRD) ml/min/1.73m 2 63±23 59± Number of comorbidities 3.6± ± CCI (Charlson Comorbidity) 2.7± ± /03/2016 United4Health Year 3 Review 15
16 Follow-up and impact on patients vital signs Differences in hemodynamic parameters such as HR have demonstrable consequences in clinical outcomes 18/03/2016 United4Health Year 3 Review 16
17 Predefined outcomes (adjusted only for length of follow-up) Intervention Comparator Absolute Difference Relative Difference (Delta, %) P- value CHF-admissions % Hospital Services CHF-days hospitalised % Number of admissions % Days hospitalised % Number of ED visits % Primary Care Services GP/cardiologist contacts % All primary care contacts % /03/2016 United4Health Year 3 Review 17
18 Adjusted primary outcomes (Logistic regression analysis) Patients in intervention group were: 4.62 times less likely to have a heart failure related hospitalisation 5.22 times less like to have days hospitalised due to HF than the patients in the comparative group. 18/03/2016 United4Health Year 3 Review 18
19 Headline Impact of study Clinical Patient Economic
20 Median Satisfaction Scores across Regions Scotland, NW Moravia, Slovenia Basque Country
21 Patient safety (mortality) Group Intervention Comparator Absolute Difference Relative Difference (Delta, %) P-value CHF-related mortality 3 (1.4%) 8 (2.3%) -0.9% -38.8% Total mortality 5 (2.3%) 19 (5.4%) -3.1% -57.1% /03/2016 United4Health Year 3 Review 21
22 Headline Impact of study Clinical Patient Economic
23 Results - CHF Average projected costs per patient of the telemonitoring intervention per 6 months Type of costs ( 2015) Scotland Basque Country Moravia Slovenia Weighted average Investment costs Variable costs Total costs Expected number of patient per year ,500/ 1,250 1,600/ /03/2016 United4Health Year 3 Review 23
24
25 Results - CHF Total costs per patient per 6 months - CHF Regression analysis found: Reduced number of ED visits and admissions ( 2015) Region Type of health care costs Costs of telemonitoring Scotland Basque Country Northwest Moravia Slovenia Change in costs of GP visits Change in costs of ED visits Change in costs of outpatient visits Change in costs of admissions -1, Total net costs per patient Weighted average , /03/2016 United4Health Year 3 Review 25
26 Conclusion - CHF study Costs per patient of telehealth intervention: Mean = 277 ( 168 to 731) Total costs per patient: Mean = ( to 465) Main reason: Cost Increase in GP and outpatient visits < reduction of admissions Comparison with Renewing Health: Costs of telehealth intervention: Mean = 606 Strength of study: Accordance with Drummond (2005) guideline Weakness of study: Estimated costs of intervention is not on patient level Clinical results based on regression analysis with subsample of patients Clinical results are mean values for all regions Large variation in regional organisation in care service 18/03/2016 United4Health Year 3 Review 26
27 Conclusions Large-scale deployment of telemonitoring for CHF is feasible Patient safety was not compromised A positive impact in CHF patients health A reduction in the use of expensive hospital services Improved continuity of care 18/03/2016 United4Health Year 3 Review 27
Aldo P. Maggioni, Kees Van Gool, Nelly Biondi, Renato Urso, Niek Klazinga, Roberto Ferrari, Nikolaos Maniadakis and Luigi Tavazzi.
Appropriateness of prescriptions of recommended treatments in OECD health systems: findings based on the Long-Term Registry of the ESC on Heart Failure Aldo P. Maggioni, Kees Van Gool, Nelly Biondi, Renato
More informationA Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom
A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom Global perspective on heart failure: what needs to change? Martin R Cowie Professor of Cardiology National
More informationIN-HF on line: patient settings (Enrollement period= )
IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients
More informationShould we invest in telemonitoring?
Should we invest in telemonitoring? CCNAP Copenhagen 16 March 2012 j.boyne@maastrichtuniversity.nl No declarations of interest to declare Presentation What is TM and why should we invest in TM? Kind of
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationQOF indicator area: Chronic Obstructive Pulmonary disease (COPD)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Chronic Obstructive Pulmonary Disease QOF indicator area:
More informationPatient identification. Telehealth
Patient identification Telehealth 2 Tunstall healthcare advisory services Return on investment (ROI) indicators To ensure the telehealth service meets or exceeds the business case upon which it was procured
More informationReal-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017
Real-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017 One of the aims of GARFIELD-AF is to assist physicians in their understanding of the risk of stroke in patients with atrial
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationNew Horizons. Long Term Conditions
New Horizons Long Term Conditions Years of this 2000 2050: The Legacy Rising at all ages People reporting a chronic condition (by age) 80 70 % of sample 60 50 40 30 0-4y 5-15y 16-44y 45-64y 65-74y 75+
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationHeart Failure Management using Telemonitoring. Joseph C. Kvedar, MD Director Center for Connected Health Partners HealthCare
Heart Failure Management using Telemonitoring Joseph C. Kvedar, MD Director Center for Connected Health Partners HealthCare About the Center for Connected Health Division of Partners IS organization Research
More informationPortable Sleep Testing in Hospitalized Patients
1 Portable Sleep Testing in Hospitalized Patients Rami Khayat, MD Heart Failure AND Public Health 6 million Americans with heart failure (>2% population 20 million people with asymptomatic cardiac impairment
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationHF-PEF: Symptoms, quality of life and mortality/morbidity
HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationDr Emma Solomon and Zoe Clifford
Evaluation of the Living Well, Taking Control Community-based Prevention and Management of Type 2 Diabetes Programme: a Study Protocol and Presentation of Preliminary Findings Dr Emma Solomon and Zoe Clifford
More informationPartners in Palliative Care Pilot Evaluation. James Cotter, MD MPH
Partners in Palliative Care Pilot Evaluation James Cotter, MD MPH Partnership HealthPlan of California County Organized Health System 14 Northern California Counties 560,000 health plan members The Problem
More informationevidence note Key points Definitions
evidence note In response to an enquiry from Quality and Efficiency Support Team, Scottish Government Number 60 March 2016 What is the clinical effectiveness, cost effectiveness and safety of home health
More informationThe Role of Information Technology in Disease Management: A Case for Heart Failure
The Role of Information Technology in Disease Management: A Case for Heart Failure Teresa De Peralta, MSN, APN-C Heart Failure Product Workflow Consultant Medtronic Population Management Level 3: As patient
More informationFINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY
FINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY What is your view of the effects of the demographic change and an ageing population on the
More informationTownsville Broadband Diabetes Telehealth Trial EVALUATION REPORT. May 2015
Townsville Broadband Diabetes Telehealth Trial EVALUATION REPORT May 2015 A report by the Centre for Applied Health Economics (CAHE), Griffith University www.healtheconomics.com.au EXECUTIVE SUMMARY BACKGROUND
More informationHeart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital
Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners
More informationHeart Failure Acute and Chronic
Heart Failure Acute and Chronic Cardiac Services in Wales Acute Heart Failure standards Chronic Heart Failure standards NWIS admissions/readmission data NHFA data 2016-17 Echo accessibility BNP availability
More informationClinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry
Clinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry J T. Parissis, A. Mebazaa, V. Bistola, I. Ikonomidis,
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Probing prognosis in heart failure Daniel R. Wagner CHL/INCCI/CRP-Santé Luxembourg Disclosures Grants: Cordis, Boston Scientific, Medtronic, Sorin, Hexacath, Abbott,
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationLas dos caras de la cretinina sérica The two sides of serum creatinine
Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1
More informationCharles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT
Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT Key Messages Heart Failure is Common Heart failure is complex Heart Failure is a major issue for the NHS Heart Failure has a worse prognosis
More informationPractical Predictive Analytics. John Cuddeback, MD, PhD AMA IPPS November 11, 2016
Practical Predictive Analytics John Cuddeback, MD, PhD AMA IPPS November 11, 2016 AMGA s Work in Analytics Advocacy: Align payment incentives around population health Programs: Help members redesign delivery
More informationDisclosures. Objectives 3/27/2017. Beki Angerstein ACNP DNP FAHA CHFN Director Advanced Practice Summa Health System
Beki Angerstein ACNP DNP FAHA CHFN Director Advanced Practice Summa Health System Disclosures Previously employed by Abbott in past 12 months Objectives Review implantable device diagnostic data for risk
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None Dietary changes and its influence on cardiovascular diseases in Asian and European countries Problems of Eastern European countries for cardiovascular disease prevention
More informationDeclaration of conflict of interest
Declaration of conflict of interest Prevalence and main features of resistant hypertension in Central and Eastern Europe: data from the G. Brambilla 1, G. Seravalle 2, R. Cifkova 3, C. Farsang 4, S. Laurent
More informationthe high CVD risk smoker
Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society
More informationContinua Health Alliance Industry Statistics
Continua Health Alliance Industry Statistics Health and Wellness statistics and insights Global statistics: Worldwide obesity has more than doubled since 1980 (WHO Fact Sheet, 2008) In 2008, 1.5 billion
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationAugust 2009 Ceri J. Phillips and Andrew Bloodworth
Cost of smoking to the NHS in Wales August 2009 Ceri J. Phillips and Andrew Bloodworth Key Findings Smoking cost NHS Wales an estimated 386 million in 2007/08; equivalent to 129 per head and 7% of total
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationUsing Technology to support Self-management in Diabetes
Using Technology to support Self-management in Diabetes Dr Scott G Cunningham, University of Dundee Michelle Brogan, Scottish Centre for Telehealth and Telecare Overview Introduction to My Diabetes My
More informationAgeing Well. The challenge of our ageing population. Martin Vernon NCD Older People. Find Recognise Assess Intervene Long-term.
Ageing Well The challenge of our ageing population Martin Vernon NCD Older People 7 th June 2017 1 Projected UK age structure Foresight, 2016 2 Ageing impacts 15 million live with a long term condition
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationAcute heart failure, beyond conventional treatment: persisting low output
Acute heart failure, beyond conventional treatment: persisting low output Alexandre Mebazaa, FESC Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationLIVE WEBINAR Boston Scientific External Use. Show and Distribute CRM AA-June 2017
LIVE WEBINAR www.hf-channel.com 1 LIVE WEBINAR AGENDA 2 The use of diagnostics in the management of HF Patients Prof. Martin Cowie 3 The patient journey is complex 4 Remote monitoring Initially, telephone
More informationSGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationΟξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες
Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Στράτος Θεοφιλογιαννάκος, MD, PhD Ιατρείο Καρδιακής Ανεπάρκειας, Γ Πανεπιστημιακή Καρδιολογική Κλινική ΑΠΘ, ΠΓΝ Ιπποκράτειο
More informationReshaping Care Pathways for Older People. Anne Hendry National Clinical Lead for Quality
Reshaping Care Pathways for Older People Anne Hendry National Clinical Lead for Quality Reshaping Care for Older People 10 Year Programme to 2021 300 million Change Fund to 2015 32 Partnerships between
More informationAcute Heart Failure 2017
Acute Heart Failure 2017 Acute Heart Failure 2017 Heart Failure Definitions HFrEF, HFmrEF. EFpEF Acute Decompensated Heart Failure De Novo presentation Decompensation of Chronic Heart Failure Longer Term
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationeplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd
eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationPOSITION STATEMENT. Diabetic eye screening April Key points
POSITION STATEMENT Title Date Diabetic eye screening April 2013 Key points Diabetic retinopathy is the most common cause of sight loss in the working age population (1) All people with any type of diabetes
More informationNATIONAL BOWEL CANCER AUDIT The validity of cancer-specific mortality as a performance indicator in patients having major surgery for bowel cancer
NATIONAL BOWEL CANCER AUDIT The validity of cancer-specific as a performance indicator in patients having major surgery for bowel cancer NBCA: Short report 4 Date of publication: Friday 13 th October 2017
More informationHeart Failure. A Marvellous Story with More to Come. Prof Ken McDonald National Clinical Lead for Heart Failure
Heart Failure A Marvellous Story with More to Come Prof Ken McDonald National Clinical Lead for Heart Failure Advances in Heart Failure over Last 20 years Pharmacotherapy in HF-REF ADHF 50-15% Community
More informationSection A: Clarification on effectiveness data. Licensed population
Section A: Clarification on effectiveness data Licensed population A1: priority question Please provide the information depicted in the following table for each of the subgroups listed below (i.e., 7 tables
More informationA Prospective Comparison of Two Commercially Available Hospital Admission Risk Scores
A Prospective Comparison of Two Commercially Available Hospital Admission Risk Scores Dale Eric Green, MD MHA FCCP: Chief Medical Information Officer, Cornerstone Health Care AMGA April, 2014 Disclosure
More informationTITLE PAGE STUDY REPORT NO
TITLE PAGE STUDY REPORT NO. 1075544 From Final Study Report: RO0452317 - F. Hoffmann-L a Roche Ltd Protocol BO20652 Report Number 1075544 1 PASS INFORMATION TITLE: AN OBSERVATIONAL STUDY OF CARDIAC EVENTS
More informationPutting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Putting NICE guidance into practice Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80) Published: November 2017 Summary This report focuses on the recommendations
More informationCKD Screening in Developing Countries. The case of Jalisco, Mexico.
CKD Screening in Developing Countries. The case of Jalisco, Mexico. Hospital Civil de Guadalajara. Hospitales Civiles de Guadalajara Foundation University of Alberta, Edmonton, CA e-mail: ggarcia1952@gmail.com
More informationUse of Sacubitril/Valsartan in Heart Failure
Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal
More informationVolunteering in NHSScotland Developing and Sustaining Volunteering in NHSScotland
NG11-07 ing in NHSScotland Developing and Sustaining ing in NHSScotland Outcomes The National Group for ing in NHS Scotland agreed the outcomes below which formed the basis of the programme to develop
More informationPatients as consumers of healthcare: the role of innovation in self-care and self-management
Engineering Innovation in the NHS Royal Academy of Engineering Conference Patients as consumers of healthcare: the role of innovation in self-care and self-management Prof. Lionel Tarassenko FREng Institute
More informationThe Health Problem: Guidelines: NHS Priority:
PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation research project.
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationResource impact report: Eating disorders: recognition and treatment (NG69)
Resource impact report: Eating disorders: recognition and treatment (NG69) Published: May 2017 Summary This report looks at the resource impact of implementing NICE s guideline on eating disorders: recognition
More informationDisclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
More informationNext-Generation Remote Patient Monitoring for Heart Failure March 3, 2016
Next-Generation Remote Patient Monitoring for Heart Failure March 3, 2016 Raj Khandwalla, MD Cedars-Sinai Medical Center Martin S. Kohn, MD, Sentrian Conflict of Interest Raj Khandwalla, M.D. M.A. FACC
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More information1/28/2016. The Weight is Over! Heart Failure Epidemic. Heart Failure Epidemic. U.S. Census Bureau Projections. Burden on Society
Remote Monitoring for Heart Failure: The Weight is Over! Heart Failure Epidemic Jamie Pelzel, MD Cardiologist, CentraCare Heart & Vascular Center Medical Director, CentraCare Heart Failure Program Kannel
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Hypertension QOF indicator area: Hypertension Date: July 2013
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More informationA New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG
A New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG Dr Rosie Heath GP Principal Church view medical centre and GPwSI Western locality Cardiology
More informationCreating Devices for Personalized Health Monitoring: Cardiovascular Monitoring Case Studies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2014 UMass Center for Clinical and Translational Science Research Retreat
More informationSetting The setting was secondary care. The economic study was carried out in Switzerland.
Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, Scholer A, Christ M, Perruchoud A P Record
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationA systems biology study to tailored treatment in chronic heart failure Ouwerkerk, W.
UvA-DARE (Digital Academic Repository) A systems biology study to tailored treatment in chronic heart failure Ouwerkerk, W. Link to publication Citation for published version (APA): Ouwerkerk, W. (2017).
More informationInfluencing planning to improve the quality of Parkinson s care in Scotland
Influencing planning to improve the quality of Parkinson s care in Scotland This short guide enables you to influence commissioning by making the case for high quality, cost-effective care for people affected
More informationSerelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure
Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure Item Type info:eu-repo/semantics/article Authors Hernández, Adrian V. Citation Eur Heart J (2014) 35
More informationTactics to Make Telehealth Pay Off
Tactics to Make Telehealth Pay Off Lin Li, Ph.D. Philips Research North America Kathleen Sullivan, RN, MSN Dignity Health 2013 NAHC Annual Meeting Oct, 2013 Today s discussion Insights gained from market
More informationTechnology-Enabled Dementia Care
Technology-Enabled Dementia Care Reducing Facility Utilization for Patients with Dementia Ceresti Health 2888 Loker Avenue, Ste. 209 Carlsbad, CA 92010 760.453.0997 www.ceresti.com Jan-19 v1.3 by Empowering
More informationEjection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA
Ejection Fraction in Heart Failure: A Redefinition Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA Word of caution!!! Incomplete understanding of a disease process may lead to
More informationEffectiveness of heart failure management: what are the key components? T. Jaarsma
Effectiveness of heart failure management: what are the key components? T. Jaarsma tiny.jaarsma@liu.se HF management ESC HF Guidelines: Crucial characteristcs Effective Disease management Multi- facetted
More informationMihai Gheorghiade MD
Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationHF-Preserved Ejection Fraction
HF-Preserved Ejection Fraction Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski Alberta Heart
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More information